Literature DB >> 1959670

Phosphoramidon inhibits the generation of endothelin-1 from exogenously applied big endothelin-1 in cultured vascular endothelial cells and smooth muscle cells.

R Ikegawa1, Y Matsumura, Y Tsukahara, M Takaoka, S Morimoto.   

Abstract

When cultured porcine aortic endothelial cells (ECs) were incubated with porcine big endothelin-1 (bit ET-1(1-39)), there was a time-dependent increase in immunoreactive (IR)-ET in the culture supernatant, in addition to an endogenous IR-ET release fron the cells. Reverse-phase HPLC of the culture supernatant revealed one major IR-ET component corresponding to the elution position of synthetic ET-1, thereby indicating that the additional increase in IR-ET was due to the conversion of big ET-1 to mature ET-1(1-21). Phosphoramidon, a metalloproteinase inhibitor, strongly suppressed this increase in IR-ET as well as the endogenous IR-ET release. Cultured vascular smooth muscle cells (VSMCs) also released IR-ET. The apparent conversion of exogenously applied big ET-1 to ET-1 and its inhibition by phosphoramidon were observed using cultured VSMCs, although the enzyme inhibitor did not influence the basal secretion of IR-ET from VSMCs. These results suggest that both cultured ECs and VSMCs can generate ET-1 from exogenously applied big ET-1 via action of the same type of phosphoramidon-sensitive metalloproteinase, which is also involved in the endogenous ET-1 generation in ECs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1959670     DOI: 10.1016/0014-5793(91)81149-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  7 in total

1.  Contractile effect of big endothelin-1 and its conversion to endothelin-1 in rabbit cerebral arteries.

Authors:  J Petersson; G C Hanson; B F Lindberg; E D Högestätt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

2.  Endothelin-1 enhances neutrophil adhesion to human coronary artery endothelial cells: role of ET(A) receptors and platelet-activating factor.

Authors:  C Zouki; C Baron; A Fournier; J G Filep
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

3.  Differential effects of phosphoramidon on contractile responses to angiotensin II in rat blood vessels.

Authors:  L Chen; J R McNeill; T W Wilson; V Gopalakrishnan
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

4.  Inhibition by phosphoramidon of the regional haemodynamic effects of proendothelin-2 and -3 in conscious rats.

Authors:  S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

5.  Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells.

Authors:  J C Yu; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

Review 6.  Insights into pathogenesis and treatment of cytokines in cardiomyopathy.

Authors:  L Vadlamani; W T Abraham
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 3.955

7.  Human breast cancer cells contain a phosphoramidon-sensitive metalloproteinase which can process exogenous big endothelin-1 to endothelin-1: a proposed mitogen for human breast fibroblasts.

Authors:  K V Patel; M P Schrey
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.